Silence Therapeutics has named Jeffrey Vick as its new CEO.
The company said it appointed Vick to “strengthen its core management team as [it] seeks to expand its business partnerships.” Silence has not had a CEO since it began refocusing on RNAi therapeutics in 2004 (see RNAi News, 7/29/2005).
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
